November 5, 2018Open Access

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22

Key Points

Key points are not available for this paper at this time.

Abstract

relapse following CD19-directed CAR therapy. The CD19/CD22 bivalent CAR provides an opportunity to test whether simultaneous targeting may reduce risk of antigen loss.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Haiying Qin

Sneha Ramakrishna

Sang M. Nguyen

Journals

Molecular Therapy — Oncolytics

Actions

Institutions

National Cancer Institute

Center for Cancer Research

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider